Saturday 17 October 2026
Export KROS’s income statement to Excel — free account
Keros Therapeutics, Inc.
KROS Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.8%, EPS fell 90.8% and free cash flow grew 32.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.66
0.44
−3.96%
Follow KROS
Keros Therapeutics, Inc. (KROS) P/E ratio
Keros Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 45.9× (September 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 10.9× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Dec 2025 | 10.9× | 9.32% |
| Sep 2025 | 10.0× | (73.75%) |
| Jun 2025 | 38.1× | — |
| 13 more quarters | Free account |
Against its own ten years
Low 0.0×
High 45.9×
Ten-year median
0.0×
Current reading's percentile
88
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MGNX MacroGenics, Inc. compare | n/m |
| KROS Keros Therapeutics, Inc. | n/m |
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| PYXS Pyxis Oncology, Inc. compare | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| EVMN Evommune Inc. compare | n/m |
| CAMP CAMP4 Therapeutics Corporation compare | n/m |
| SLGL Sol-Gel Technologies Ltd. compare | n/m |
| PLX Protalix BioTherapeutics, Inc. compare | 10.9× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)